Loading patent…
AssigneeMetaproteomics, LLC
InventorsMatthew L. Tripp, John G. Babish, Jeffrey S. Bland, Veera Konda, Anu Desai, Gary Darland, Brian J. Carroll, James S. Traub, Linda M. Pacioretty, Dennis Emma
Estimating the term…
Compounds and methods for multi-targeted protein kinase modulation for angiogenesis, cancer treatment or the inflammatory pathways associated with those conditions are disclosed. The compounds and methods disclosed are based on substituted 1,3-cyclopentadione compounds.
A method to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said method comprising administering to the mammal a therapeutically effective amount of a substituted 1,3-cyclopentadione compound.
The method of claim 6, wherein the composition further comprises one or more members selected from the group consisting of antioxidants, vitamins, minerals, proteins, fats, and carbohydrates.
A method to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said method comprising administering to the mammal a therapeutically effective amount of a substituted 1,3-cyclopentadione compound.
A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of a cis-n-tetrahydro-isoalpha acid (TH5) as the only substituted 1,3-cyclopentadione compound in the composition;
A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition consisting essentially of therapeutically effective amounts of one or more (n) analogs of substituted 1,3-cyclopentadione compound and optionally one or more (ad) analogs of substituted 1,3-cyclopentadione compound in the composition;
A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition consisting essentially of therapeutically effective amount of one or more (co) analogs of substituted 1,3-cyclopentadione compound in the composition;
A composition to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of a cis-n-tetrahydro-isoalpha acid (TH5) as the only substituted 1,3-cyclopentadione compound in the composition;
A composition to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition consisting essentially of therapeutically effective amounts of one or more (a) analogs of substituted 1,3-cyclopentadione compound and optionally one or more (ad) analogs of substituted 1,3-cyclopentadione compound in the composition;
A composition to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition consisting essentially of therapeutically effective amount of one or more (co) analogs of substituted 1,3-cyclopentadione compound in the composition;
A composition to treat a cancer responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of only one analog of a substituted 1,3-cyclopentadione compound;
A composition to treat angiogenic conditions responsive to protein kinase modulation in a mammal in need thereof, said composition comprising a therapeutically effective amount of only one analog of a substituted 1,3-cyclopentadione compound;
Dependencies are inferred from the claim text.